Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study

Articles

Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled studyBackground: Depression is often associated with sexual dysfunction, and pharmacologic treatment for hypoactive sexual desire disorder can be considered in women receiving treatment for depression. Aim: To evaluate the safety of flibanserin in women treated for depression with selective serotonin reuptake inhibitors or serotonin…

Flibanserin for hypoactive sexual desire disorder: an open-label safety study

Articles

Flibanserin for hypoactive sexual desire disorder: an open-label safety studyBackground: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study. Aim: To examine the safety and tolerability of flibanserin 100 mg once daily at bedtime in the treatment of premenopausal and…

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder

Articles

Open-label extension study of flibanserin in women with hypoactive sexual desire disorderIntroduction: Hypoactive Sexual Desire Disorder (HSDD) is a common form of Female Sexual Dysfunction characterized by low sexual desire that causes distress or interpersonal difficulty. Aim: This 52-week open-label extension study aimed to assess the safety and tolerability of flibanserin, a postsynaptic 5-HT(1A) agonist/5-HT(2A)…